The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...

The move to self-administration with a syringe and needle, just like how insulin is often taken for diabetes, means a whole ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

When it comes to managing type 2 diabetes and supporting weight loss, patients often face the choice between Semaglutide ...

Weight loss injections are essentially the opposite of pills in terms of pros and cons. They’re generally more effective and ...

Novo Nordisk, maker of Ozempic and Wegovy, now has a market capitalization of more than ... paying patients who are willing ...

The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence ...

Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...

A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...